Amarin (AMRN, $21.33) shares jump +10% on higher revenue guidance
Amarin raised outlook on revenue, sending its shares surging +10% Tuesday.
The biopharmaceutical company lifted its 2019 revenue guidance to a range of between $380 million and $420 million, up from prior forecast of $350 million.
The company’s higher guidance comes on the back of its optimism about its Vascepa treatment for chronic cardiovascular disease. It is hopeful that Vascepa will generate “billions of dollars in revenue in the years to come”.
Amarin reported first-quarter revenue of $73.3 million, which represents a 67% jump from the same quarter of the previous year. It is also higher than the $67.3 million expected by analysts polled by FactSet.
AMRN's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AMRN turned positive on June 09, 2026. Looking at past instances where AMRN's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 09, 2026. You may want to consider a long position or call options on AMRN as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
AMRN moved above its 50-day moving average on June 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AMRN crossed bullishly above the 50-day moving average on June 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AMRN advanced for three days, in of 250 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AMRN moved out of overbought territory on June 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 52 cases where AMRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMRN broke above its upper Bollinger Band on June 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMRN entered a downward trend on June 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMRN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.738) is normal, around the industry mean (19.568). AMRN has a moderately low P/E Ratio (0.000) as compared to the industry average of (26.482). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.849). AMRN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (1.519) is also within normal values, averaging (3.939).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on commercialization and development of therapeutics to improve cardiovascular health
Industry PharmaceuticalsMajor
Advertisement